Decoy Therapeutics Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 78/100
What the filing says
On June 29, 2026, Decoy Therapeutics Inc. issued three series of warrants (A, B, C) to Armistice Capital Master Fund Ltd., totaling 2,961,085 common shares exercisable at $5.91/share. Series A: 592,217 shares (milestone: Phase 1 CTA filing in EEA); Series B: 1,184,434 shares (milestone: Phase 2a UK trial MHRA approval); Series C: 1,184,434 shares (milestone: Phase 2a primary endpoint announcement). All expire June 29, 2031 or 90 days post-milestone, whichever is earlier. Exercise contingent on stockholder approval.
Why this rating
Substantial capital-structure dilution but signals investor confidence; warrants tied to clinical milestones reduce immediate shareholder economic impact. Relative to $1.9M market cap, represents major equity commitment.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.